Critical Comparison: TuHURA Biosciences (NASDAQ:HURA) & Nkarta (NASDAQ:NKTX)

TuHURA Biosciences (NASDAQ:HURA) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Profitability

This table compares TuHURA Biosciences and Nkarta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Nkarta	N/A	-30.90%	-24.20%

Risk and Volatility

TuHURA Biosciences has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for TuHURA Biosciences and Nkarta, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1	0	5	0	2.67
Nkarta	1	0	4	1	2.83

TuHURA Biosciences currently has a consensus target price of $9.00, indicating a potential upside of 314.75%. Nkarta has a consensus target price of $10.75, indicating a potential upside of 414.35%. Given Nkarta’s stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than TuHURA Biosciences.

Institutional and Insider Ownership

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares TuHURA Biosciences and Nkarta”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05 million	($0.61)	-3.56
Nkarta	N/A	N/A	-$104.08 million	($1.34)	-1.56

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Summary

Nkarta beats TuHURA Biosciences on 9 of the 12 factors compared between the two stocks.

About TuHURA Biosciences

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

About Nkarta

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.